ArticleWorld journal of methodology2026
Mirtazapine for the treatment of irritable bowel syndrome: A systematic review.
Article in World journal of methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrritable bowel syndrome (IBS) is a common functional bowel disorder characterized by abdominal pain and altered bowel habits, with types classified based on stool patterns: (1) Diarrhea-predominant IBS (IBS-D); (2) IBS with constipation (IBS-C); and (3) Mixed IBS. This condition affects approximately 10% of adults globally and is challenging to treat due to the lack of definitive structural or biochemical markers. Treatment options include dietary, pharmacological, and psychological therapies, yet patients often struggle with refractory symptoms impacting quality of life (QoL).
aimTo review existing literature to evaluate Mirtazapine's effectiveness in treating IBS, particularly in older patients.
methodsThis review as registered in the PROSPERO database (CRD420251022721) and followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A systematic review was conducted between February 2024 and March 2024, searching PubMed, EMBASE, and BMJ Case Reports from database inception to present. We included English-language randomized controlled trials (RCTs), prospective clinical studies, and case reports of adult IBS-D or IBS-C patients treated with Mirtazapine, reporting on symptom resolution, abdominal pain, insomnia, or related outcomes. Data extraction covered study design, sample size, dosage, duration, and outcomes. No meta-analysis was performed due to heterogeneity.
resultsOf 77 identified references, five publications met inclusion criteria: (1) Three case reports; (2) One double-blind RCT (
conclusionAlthough evidence is limited, current data indicate Mirtazapine improves IBS-related symptoms and associated mental health issues, with rapid onset and good tolerability. The small number of studies and absence of large-scale RCTs warrant cautious interpretation. Further RCTs are essential to confirm Mirtazapine's role in IBS treatment and define optimal patient profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.